CEVI Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for CEVI from our risk checks.
My Notes
Capture your thoughts, links and company narrative
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 222.00 |
| 52 Week High | SEK 302.00 |
| 52 Week Low | SEK 197.20 |
| Beta | 1.22 |
| 1 Month Change | 2.07% |
| 3 Month Change | -3.90% |
| 1 Year Change | 7.51% |
| 3 Year Change | -33.89% |
| 5 Year Change | -30.30% |
| Change since IPO | 1,323.08% |
Recent News & Updates
Is Now The Time To Put CellaVision (STO:CEVI) On Your Watchlist?
Jan 21
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27Recent updates
Is Now The Time To Put CellaVision (STO:CEVI) On Your Watchlist?
Jan 21Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Is CellaVision (STO:CEVI) A Risky Investment?
Jun 07Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
May 22CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
Apr 13CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Apr 09CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly
Sep 23CellaVision (STO:CEVI) May Have Issues Allocating Its Capital
Aug 16Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 02We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease
Jun 27What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?
May 31Shareholder Returns
| CEVI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 3.5% | 5.6% | 1.1% |
| 1Y | 7.5% | -0.2% | 13.3% |
Return vs Industry: CEVI exceeded the Swedish Medical Equipment industry which returned -0.2% over the past year.
Return vs Market: CEVI underperformed the Swedish Market which returned 13.3% over the past year.
Price Volatility
| CEVI volatility | |
|---|---|
| CEVI Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.7% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: CEVI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CEVI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
CellaVision AB (publ) Fundamentals Summary
| CEVI fundamental statistics | |
|---|---|
| Market cap | SEK 5.10b |
| Earnings (TTM) | SEK 150.21m |
| Revenue (TTM) | SEK 737.16m |
35.3x
P/E Ratio7.2x
P/S RatioIs CEVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEVI income statement (TTM) | |
|---|---|
| Revenue | SEK 737.16m |
| Cost of Revenue | SEK 243.34m |
| Gross Profit | SEK 493.83m |
| Other Expenses | SEK 343.61m |
| Earnings | SEK 150.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 66.99% |
| Net Profit Margin | 20.38% |
| Debt/Equity Ratio | 4.6% |
How did CEVI perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 20:56 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |